VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | Managing myeloma during COVID-19: German perspective

Katja Weisel • 31 May 2020
COMy Virtual 2020
Multiple Myeloma Bortezomib Dexamethasone Melphalan Thalidomide

Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, shares her experience of the impact of COVID-19 in the management of multiple myeloma (MM) patients in Germany. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Katja Weisel

3:04
DREAMM-3: belantamab mafodotin vs pom/dex for R/R myeloma
Katja Weisel • 31 May 2020
4:25
The benefits of lenalidomide and dexamethasone for multiple myeloma
Katja Weisel • 3 Jun 2016
5:17
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Katja Weisel • 31 May 2020
1:23
Maintenance therapy for MRD negativity in MM
Katja Weisel

Related Videos

4:24
Treating later relapses in patients with multiple myeloma
Stefan Knop • 12 Apr 2021
4:39
Treating MGRS and MGUS with neuropathy
Stefan Knop • 12 Apr 2021
4:05
Elotuzumab, pomalidomide, and dexamethasone for advanced myeloma
Stefan Knop • 12 Apr 2021
5:24
Novel immunotherapies for multiple myeloma
Daniel Auclair • 8 Apr 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals